S

SeaStar Medical Holding Corp
NASDAQ:ICU

Watchlist Manager
SeaStar Medical Holding Corp
NASDAQ:ICU
Watchlist
Price: 4.24 USD -4.93% Market Closed
Market Cap: $16.9m

EV/EBIT

-0.4
Current
24%
Cheaper
vs 3-y average of -0.6

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
-0.4
=
Enterprise Value
$5.6m
/
EBIT
$-12.2m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
-0.4
=
Enterprise Value
$5.6m
/
EBIT
$-12.2m

Valuation Scenarios

SeaStar Medical Holding Corp is trading above its industry average

If EV/EBIT returns to its Industry Average (19.2), the stock would be worth $-193.94 (4 674% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-4 763%
Maximum Upside
No Upside Scenarios
Average Downside
4 718%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple -0.4 $4.24
0%
Industry Average 19.2 $-193.94
-4 674%
Country Average 19.6 $-197.7
-4 763%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 8 638 companies
0th percentile
-0.4
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

SeaStar Medical Holding Corp
Glance View

Market Cap
16.9m USD
Industry
Health Care

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Tampa, Florida. The company went IPO on 2021-01-26. The firm is focused on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. The firm's technologies rely on science to provide life-saving solutions to critically ill patients. The firm is engaged in developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

ICU Intrinsic Value
1.35 USD
Overvaluation 68%
Intrinsic Value
Price $4.24
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett